Safety of intrathecal route: focus to methylprednisolone acetate (Depo-Medrol) use.

about

Safety of intrathecal route: focus to methylprednisolone acetate (Depo-Medrol) use.

Item

http://www.wikidata.org/entity/Q47335987

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Safety of intrathecal route: focus to methylprednisolone acetate (Depo-Medrol) use.

@en

Safety of intrathecal route: focus to methylprednisolone acetate

@nl

type

Item

label

Safety of intrathecal route: focus to methylprednisolone acetate (Depo-Medrol) use.

@en

Safety of intrathecal route: focus to methylprednisolone acetate

@nl

prefLabel

Safety of intrathecal route: focus to methylprednisolone acetate (Depo-Medrol) use.

@en

Safety of intrathecal route: focus to methylprednisolone acetate

@nl

P1476

Safety of intrathecal route: focus to methylprednisolone acetate (Depo-Medrol) use.

@en

P2093

David Nguyen

http://www.w3.org/2001/XMLSchema#string

Jean-Eudes Fontan

http://www.w3.org/2001/XMLSchema#string

Michèle Zamy

http://www.w3.org/2001/XMLSchema#string

Sofiane Kabiche

http://www.w3.org/2001/XMLSchema#string

P2860

Cytokines and particle-induced inflammatory cell recruitment

Contact allergy to miripirium chloride in Depo-Medrol.

Sclerosing spinal pachymeningitis. A complication of intrathecal administration of Depo-Medrol for multiple sclerosis

The long-term safety and efficacy of intrathecal therapy using sufentanil in chronic intractable non-malignant pain.

Intrathecal chemotherapy.

Intrathecal chemotherapy for hematologic malignancies: drugs and toxicities.

Allergic otitis externa.

Excipient-drug interactions in parenteral formulations.

Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic l

Intrathecal trastuzumab for leptomeningeal carcinomatosis in patients with human epidermal growth factor receptor 2 positive breast cancer

P2888

s00586-017-5387-x

P304

21-30

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00586-017-5387-X

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Salvatore Cisternino

Joël Schlatter

P577

2017-11-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29151132

http://www.w3.org/2001/XMLSchema#string